科济生物医药（上海）有限公司 Mediaroom

CARsgen Therapeutics Announces 2025 Annual Results

SHANGHAI, March 6, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2026-03-06 20:03 9776

CARsgen Therapeutics Announces 2025 Annual Results

CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors

SHANGHAI, PHILADELPHIA and SAN FRANCISCO, Jan. 12, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdin...

2026-01-12 21:05 5602

CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors

CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596

SHANGHAI, Dec. 28, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2025-12-29 08:10 4187

CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2025-12-08 10:08 3561

CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2025-12-08 08:15 3185

CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue

SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2025-12-07 17:21 3655

CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue

CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B

SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2025-11-03 22:15 3176

CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025

SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2025-10-20 08:15 2881

Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia

SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Primary plasma cell leukemia (pPCL) is a rare and highly ag...

2025-10-19 14:00 2300

CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology

SHANGHAI, Oct. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2025-10-08 08:15 1840

CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025

SHANGHAI, Sept. 17, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK...

2025-09-18 08:15 2496

CARsgen Therapeutics Announces 2025 Interim Results

SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2025-08-15 08:15 3470

CARsgen Therapeutics Announces 2025 Interim Results

CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO

SHANGHAI, July 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2025-07-14 08:00 1982

CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting

SHANGHAI, June 1, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2025-06-02 08:15 2107

CARsgen's Satri-cel Granted Priority Review by the NMPA

SHANGHAI, May 28, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2025-05-28 12:10 2299

CARsgen's Satri-cel Abstract Available on ASCO Website

SHANGHAI, May 22, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2025-05-23 08:00 2497

CARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and Efficacy

SHANGHAI, May 11, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2025-05-12 08:00 2610

Latest News

CARsgen Therapeutics Announces 2025 Annual Results

CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors

CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596

CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue

CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B

CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025

Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia

CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology

CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025

CARsgen Therapeutics Announces 2025 Interim Results

CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO

CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting

CARsgen's Satri-cel Granted Priority Review by the NMPA

CARsgen's Satri-cel Abstract Available on ASCO Website

CARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and Efficacy

CARsgen Announced 2024 Annual Results

CARsgen's Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA

CARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in a Patient with Autoimmune Disease